MARKET

ICCC

ICCC

ImmuCell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.02
+0.18
+1.78%
Opening 12:28 06/16 EDT
OPEN
10.00
PREV CLOSE
9.84
HIGH
10.25
LOW
10.00
VOLUME
5.76K
TURNOVER
--
52 WEEK HIGH
13.20
52 WEEK LOW
4.370
MARKET CAP
77.48M
P/E (TTM)
-53.8790
1D
5D
1M
3M
1Y
5Y
Here's Why ImmuCell Corporation's (NASDAQ:ICCC) CEO May Deserve A Raise
Shareholders will be pleased by the impressive results for ImmuCell Corporation ( NASDAQ:ICCC ) recently and CEO...
Simply Wall St. · 6d ago
Animal Vaccine Market Key Insights Based on Product Type, End-use and Regional Demand
Japan, Japan, Wed, 26 May 2021 01:57:03 / Comserve Inc. / -- Animal Vaccine Market With Top Countries Data, Industry Analysis , Size, Share, Revenue, Prominent Players, Developing Technologies, Tendencies and Forecast
Comserve · 05/26 05:58
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today...
GlobeNewswire · 05/19 16:00
ImmuCell Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2021 / ImmuCell Corp. (NASDAQ:ICCC) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 14, 2021 at 9:00 AM Eastern Time.
ACCESSWIRE · 05/14 11:15
ImmuCell Q1 EPS $(0.06) Misses $0.05 Estimate, Sales $4.11M Miss $5.40M Estimate
ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.05 by 220 percent. This is a 200 percent decrease over losses of $(0.02) per share from the same
Benzinga · 05/13 21:00
BRIEF-Immucell Announces Unaudited Financial Results For The First Quarter Ended March 31, 2021
reuters.com · 05/13 20:41
ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today...
GlobeNewswire · 05/13 20:23
ImmuCell reports Q1 results
ImmuCell (ICCC): Q1 GAAP EPS of -$0.06.Revenue of $4.1M (-16.5% Y/Y)Press Release
Seekingalpha · 05/13 20:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICCC. Analyze the recent business situations of ImmuCell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICCC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 1.17M
% Owned: 15.17%
Shares Outstanding: 7.74M
TypeInstitutionsShares
Increased
8
66.23K
New
4
38.92K
Decreased
6
40.85K
Sold Out
2
23.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.70%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Director
David Tomsche
President/Chief Executive Officer/Treasurer/Secretary/Director
Michael Brigham
Chief Scientific Officer/Vice President
Joseph Crabb
Vice President/Director of Sales/Director of Marketing/Director
Bobbi Brockmann
Vice President
Elizabeth Williams
Independent Director
David Cunningham
Independent Director
Steven Rosgen
Independent Director
Jonathan Rothschild
Independent Director
Paul Wainman
No Data
About ICCC
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

Webull offers kinds of ImmuCell Corporation stock information, including NASDAQ:ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.